More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.96B
EPS
1.54
P/E ratio
32.3
Price to sales
6.47
Dividend yield
--
Beta
1.978
Previous close
$24.01
Today's open
$23.99
Day's range
$23.60 - $24.47
52 week range
$21.91 - $60.91
show more
CEO
Marc Stapley
Employees
755
Headquarters
South San Francisco, CA
Exchange
NASDAQ Global Market
Shares outstanding
80695480
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. In addition to Twilio, West Pharmaceutical and RBC Bearings, we added to Neptune Insurance, Lattice Semiconductor and Cognex during the quarter. In addition to Modine Manufacturing, we ended our investment campaigns in Monolithic Power Systems and Tradeweb Markets.
Seeking Alpha • 8 hours ago

Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky
Needham reportedly cut its Veracyte price target by $23 per share after the Company's November 4, 2026 outlook reset on its Decipher Prostate test. An investigation into potential securities law violations is underway on behalf of VCYT shareholders who lost money.
PRNewsWire • Nov 12, 2026

Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
Veracyte is rated Hold, as its valuation premium has vanished, but growth prospects have weakened, especially for Decipher prostate cancer testing. Decipher's test volume growth is slowing sharply, with management now planning for a 40% lower annual increase versus prior years. VCYT trades at 2.87x forward sales and 12.95x earnings, below sector medians, yet consensus expects a 19.38% EPS decline in 2027.
Seeking Alpha • Nov 12, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)
Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk
GlobeNewsWire • Nov 10, 2026

Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript
Veracyte, Inc. ( VCYT ) 2026 UBS Global Healthcare Conference November 10, 2026 4:15 PM EST Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good afternoon.
Seeking Alpha • Nov 11, 2026

VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $VCYT--VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law.
Business Wire • Nov 9, 2026

VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte
Veracyte shares fell after its November 4, 2026 report despite $151.8 million in third-quarter revenue and a new $100 million buyback, as the market reacted to a weaker Decipher Prostate outlook. An investigation concerns potential securities law violations.
PRNewsWire • Nov 6, 2026

Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
Zacks Investment Research • Nov 6, 2026

Veracyte Crashes Almost 40% On Seismic Shift For Its Best-Selling Test
Veracyte stock crashed almost 40% early Thursday after the company reset growth expectations for its prostate cancer tissue test, Decipher.
Investors Business Daily • Nov 5, 2026

What Veracyte (VCYT) Said on Its Q3 Earnings Call
Veracyte NASDAQ: VCYT reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management's forecast. The company also outlined a preliminary 2027 outlook for mid-single-digit revenue growth as it invests in its commercial teams and expands its cancer testing portfolio.
MarketBeat • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Veracyte Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.